ACM
AVBP icon

ADAR1 Capital Management’s ArriVent BioPharma AVBP Stock Holding History

ADAR1 Capital Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-141,814
Closed -$3.27M – 347
2026
Q1 		$3.27M Buy
+141,814
New +$3.2M 0.19% 101

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ADAR1 Capital Management's AVBP Position: Q2 2026 in Review

ADAR1 Capital Management sold out of ArriVent BioPharma (AVBP) in Q2 2026, closing a stake of 141,814 shares — an estimated $3.27M sold.

ADAR1 Capital Management first reported a position in AVBP in Q1 2026 and held it in 1 quarter. The position peaked at $3.27M in Q1 2026. 158 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • ADAR1 Capital Management reported no remaining ArriVent BioPharma position as of Q2 2026 after selling out during the quarter.
  • ADAR1 Capital Management sold 141,814 ArriVent BioPharma shares in Q2 2026, an estimated $3.27M.
  • ADAR1 Capital Management first reported a position in ArriVent BioPharma in Q1 2026 and held it in 1 quarter.
  • ADAR1 Capital Management's ArriVent BioPharma position peaked at $3.27M in Q1 2026.
  • 158 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.